SK Biopharmaceuticals Co., Ltd. (KRX:326030)
91,600
+1,300 (1.44%)
Last updated: May 29, 2025
SK Biopharmaceuticals Revenue
SK Biopharmaceuticals had revenue of 144.38B KRW in the quarter ending March 31, 2025, with 26.67% growth. This brings the company's revenue in the last twelve months to 578.00B, up 41.64% year-over-year. In the year 2024, SK Biopharmaceuticals had annual revenue of 547.60B with 54.30% growth.
Revenue (ttm)
578.00B
Revenue Growth
+41.64%
P/S Ratio
12.41
Revenue / Employee
2.40B
Employees
241
Market Cap
7,173.49B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 547.60B | 192.70B | 54.30% |
Dec 31, 2023 | 354.89B | 108.71B | 44.16% |
Dec 31, 2022 | 246.18B | -172.47B | -41.20% |
Dec 31, 2021 | 418.64B | 392.65B | 1,510.23% |
Dec 31, 2020 | 26.00B | -97.85B | -79.01% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Samsung Biologics | 4,898.69B |
Celltrion | 3,662.23B |
ALTEOGEN | 151.65B |
Yuhan | 2,114.76B |
HLB Co., Ltd. | 74.64B |
Peptron | 3.15B |
PharmaResearch | 392.31B |
LigaChem Biosciences | 125.90B |